CB 839

Drug Profile

CB 839

Alternative Names: CB-839

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Calithera Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I/II Malignant melanoma; Non-small cell lung cancer
  • Phase I Haematological malignancies; Leukaemia; Solid tumours

Most Recent Events

  • 16 Mar 2017 Efficacy data from a phase I trial in Solid tumours presented at the San Antonio Breast Cancer Symposium (SABCS-2016)
  • 22 Feb 2017 Calithera Biosciences plans a phase II trial for Breast cancer (Metastatic disease) (NCT03057600)
  • 14 Feb 2017 M.D. Anderson Cancer Center in collaboration with National Cancer Institute and Calithera Biosciences plans a phase Ib/II trial for Myelodysplastic syndrome in USA (NCT03047993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top